Nebulized Tranexamic Acid for Hemoptysis

Clinical Considerations

• The pharmacologic rationale for nebulized tranexamic acid (TXA) is sound, as in vitro studies suggest a 10 μg/mL concentration inhibits fibrinolysis, achievable with nebulized delivery to bleeding airways 1
• Active disseminated intravascular coagulation (DIC) is an absolute contraindication for TXA, as it may worsen the condition by inhibiting breakdown of widespread clots 1, 2
• Massive hematuria is also an absolute contraindication due to the risk of ureteric obstruction from clot formation 2
• Renal impairment requires dose reduction due to the risk of neurotoxicity and ocular toxicity, as TXA is renally excreted 2, 3
• Active thromboembolic disease or recent thrombosis history warrants careful risk-benefit assessment 2
• Subarachnoid hemorrhage is a contraindication for systemic TXA due to cerebral edema/infarction risk; applicability to the nebulized route is unclear 3
• Nebulized TXA should be viewed as temporizing or adjunctive therapy, not a substitute for bronchoscopy, bronchial artery embolization, or surgical intervention when indicated, as its mechanism requires direct contact with the bleeding site and systemic absorption from nebulization is minimal 1